Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Prostate cancer Stories

2014-02-23 23:02:43

The use of a new technology called High Intensity Focused Ultrasound (HIFU) waves to treat prostate cancer without surgery on an out-patient basis moves closer to U.S. approval thanks to Dr. Michael J. Lazar, Jr. and other urologists utilizing this next-generation technology with patients in other nations. SANTA ROSA, California (PRWEB) February 23, 2014 HIFU technology achieves pinpoint accuracy using an “acoustic scalpel” that destroys prostate cancer, while sparing healthy tissue...

2014-02-23 23:01:48

A new study says patients with diabetes are more likely to be readmitted to the hospital after bladder cancer surgery. Raleigh, NC (PRWEB) February 23, 2014 According to new research published in the Journal of Urology and reported by Cancer Monthly, diabetic patients do not typically recover as well after urological operations like bladder cancer surgery, and develop more complications, than do non-diabetic patients. The study evaluated the 30-day unplanned readmission rates of 7,795...

2014-02-21 23:04:54

Transparency Market Research published new report "Pre-Clinical Imaging Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012 - 2018" to its data store. Browse full report: http://www.transparencymarketresearch.com/pre-clinical-imaging.html. Albany, New York (PRWEB) February 21, 2014 Pre-clinical imaging is an efficient tool for the evaluation of the anatomical, functional, and physiological status of any organ at a cellular and molecular level. This...

2014-02-20 23:32:07

Profound Medical announces initiation of U.S. clinical trial for its novel, minimally invasive technology for the treatment of localized prostate cancer. Toronto, Ontario (PRWEB) February 20, 2014 Today, Profound Medical Inc. announced the initiation of the TULSA (Trans Urethral Ultrasound Ablation) clinical trial in the United States. The first US patient was treated on January 25, 2014 and the procedure was performed at Beaumont Hospital, Royal Oak by urologist, James Relle, M.D. “We...

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...

2014-02-19 23:24:56

Taiwanese author says his research should relieve concern among diabetics that insulin might raise their cancer risk. Raleigh, NC (PRWEB) February 19, 2014 Cancer Monthly is reporting on a recently-published meta-analysis of diabetes patients that appears to show no increased risk of bladder cancer as a result of using human insulin. The large-scale study analyzed the health insurance reimbursement databases of 785,234 type 2 diabetes patients from 1996 to 2009. In 2009, the entire...

2014-02-19 23:00:12

Research Study Testing Effectiveness of New Outpatient Treatment for Localized Prostate Cancer Royal Oak, MI (PRWEB) February 20, 2014 Urologists at Beaumont Hospital, Royal Oak are first in the U.S. to treat localized prostate cancer with a transurethral ultrasound therapy guided by magnetic resonance imaging. The experimental treatment is designed to potentially reduce the long-term complications of traditional prostate cancer treatments. The first treatment on Jan. 25 marked the launch...

2014-02-19 08:31:13

-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC), showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm...

2014-02-18 08:29:52

NEW YORK, Feb. 18, 2014 /PRNewswire/ -- New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing. Life sciences company MetaStat, Inc. (OTCQB: MTST) recently completed a trial of its MetaSite Breast test that confirmed the test's ability to accurately predict whether breast cancer would metastasize. The confirmation...

2014-02-17 23:21:07

Scientists find a “modest but clinically significant” link between the diabetes drug and bladder cancer. Raleigh, NC (PRWEB) February 17, 2014 The authors of a new study published in the British Journal of Clinical Pharmacology and detailed by Cancer Monthly recommend that doctors who treat diabetes limit their patients’ exposure to the drug piaglitazone (Actos) to reduce their risk of bladder cancer. The research team from Liverpool conducted a search of the medical literature for...